{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T16:13:18Z","timestamp":1772727198945,"version":"3.50.1"},"reference-count":38,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2023,12,27]],"date-time":"2023-12-27T00:00:00Z","timestamp":1703635200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Cancer management faces a substantial challenge posed by the aging demographic. Aging is marked by accumulated DNA damage, and this phenomenon is implicated in the process of tumorigenesis. The concept of immunosenescence, postulated to manifest in elderly individuals, is defined by an age-related decline in T cells and a simultaneous elevation in proinflammatory status, leading to a diminished efficacy in response to immunotherapy. Notably, despite the rising prevalence of cancer in the elderly population, their underrepresentation in clinical trials persists. This underscores the unmet need to evaluate the safety and efficacy of cancer treatment in the elderly. This retrospective, single-center cohort study aimed to assess and evaluate the effectiveness and safety of immunotherapy in patients compared to younger individuals with metastatic solid tumors receiving ICI. A total of 220 patients were included, mostly males, with a median age of 64. The proportion of patients \u2265 65 years old was 56.5%. The use of ICI showed no significant differences concerning overall survival (OS) and progression-free survival (PFS) among age groups across different cancer types (melanoma, non-small-cell lung cancer (NSCLC), renal, and bladder cancer; p = 0.388). Concerning the response to treatment in renal cancer patients, a significant difference was observed (p = 0.041), suggesting a potential negative impact of age on the treatment response. In patients that presented immune-related adverse events (irAEs), oral corticosteroid therapy was marginally associated (p = 0.059) with the elderly population. When evaluating the NSCLC population alone (n = 131, 59.5%), our study revealed a strong association between the development of irAEs, patients\u2019 PFS and OS, and the duration of ICI treatment, but not directly correlated with age. The NSCLC elderly population presented a marginally greater number of irAEs, although without statistical significance (p = 0.86). ICI maintained efficacy and safety in elderly patients, challenging the notion that age alone should determine treatment decisions. The findings emphasize the necessity of a comprehensive geriatric assessment rather than relying solely on chronological age for personalized cancer treatment in the elderly population. Further prospective studies are needed to better understand immune responses in older adults and derive predictive biomarkers for cancer treatment.<\/jats:p>","DOI":"10.3390\/cancers16010145","type":"journal-article","created":{"date-parts":[[2023,12,27]],"date-time":"2023-12-27T10:23:54Z","timestamp":1703672634000},"page":"145","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Immunotherapy in Elderly Patients\u2014Single-Center Experience"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5503-1021","authenticated-orcid":false,"given":"Maria Jo\u00e3o","family":"Ramos","sequence":"first","affiliation":[{"name":"Medical Oncology Department, Centro Hospitalar Universit\u00e1rio de Santo Ant\u00f3nio, 4099-001 Porto, Portugal"}]},{"given":"Ana Sofia","family":"Mendes","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Centro Hospitalar Universit\u00e1rio de Santo Ant\u00f3nio, 4099-001 Porto, Portugal"}]},{"given":"Raquel","family":"Rom\u00e3o","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Centro Hospitalar Universit\u00e1rio de Santo Ant\u00f3nio, 4099-001 Porto, Portugal"}]},{"given":"Joana","family":"Febra","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Centro Hospitalar Universit\u00e1rio de Santo Ant\u00f3nio, 4099-001 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7267-3584","authenticated-orcid":false,"given":"Ant\u00f3nio","family":"Ara\u00fajo","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Centro Hospitalar Universit\u00e1rio de Santo Ant\u00f3nio, 4099-001 Porto, Portugal"},{"name":"Oncology Research Unit, UMIB\u2014Unit for Multidisciplinary Research in Biomedicine, ICBAS\u2014School of Medicine and Biomedical Sciences, Universidade do Porto, 4050-346 Porto, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2023,12,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1093\/annonc\/mdy228","article-title":"Addressing the quality of life needs of older patients with cancer: A SIOG consensus paper and practical guide","volume":"29","author":"Bossi","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1002\/ijc.33232","article-title":"Estimated global cancer incidence in the oldest adults in 2018 and projections to 2050","volume":"148","author":"Pilleron","year":"2021","journal-title":"Int. J. Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/s41568-019-0222-9","article-title":"How the ageing microenvironment influences tumour progression","volume":"20","author":"Fane","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1126\/science.aax0860","article-title":"T cells with dysfunctional mitochondria induce multimorbidity and premature senescence","volume":"368","author":"Aranda","year":"2020","journal-title":"Science"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"viii6","DOI":"10.1093\/annonc\/mds256","article-title":"Immuno-oncology: Understanding the function and dysfunction of the immune system in cancer","volume":"23","author":"Finn","year":"2012","journal-title":"Ann. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/nrm3823","article-title":"Cellular senescence: From physiology to pathology","volume":"15","author":"Serrano","year":"2014","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.cell.2019.10.005","article-title":"Cellular Senescence: Defining a Path Forward","volume":"179","author":"Gorgoulis","year":"2019","journal-title":"Cell"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1016\/j.cell.2013.05.039","article-title":"The hallmarks of aging","volume":"153","author":"Blasco","year":"2013","journal-title":"Cell"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1093\/geront\/4.4.195","article-title":"The immunologic theory of aging","volume":"4","author":"Walford","year":"1964","journal-title":"Gerontologist"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.exger.2017.10.024","article-title":"Age and immunity: What is \u201cimmunosenescence\u201d?","volume":"105","author":"Pawelec","year":"2018","journal-title":"Exp. Gerontol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/s41392-023-01451-2","article-title":"Immunosenescence: Molecular mechanisms and diseases","volume":"8","author":"Liu","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1186\/s13045-020-00986-z","article-title":"Immunosenescence: A key player in cancer development","volume":"13","author":"Lian","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1749-6632.2000.tb06651.x","article-title":"Inflamm-aging. An evolutionary perspective on immunosenescence","volume":"908","author":"Franceschi","year":"2000","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Aiello, A., Accardi, G., Candore, G., Caruso, C., Colomba, C., Di Bona, D., Duro, G., Gambino, C.M., Ligotti, M.E., and Pandey, J.P. (2019). Role of Immunogenetics in the Outcome of HCMV Infection: Implications for Ageing. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20030685"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s12979-018-0117-8","article-title":"Immune-inflammatory responses in the elderly: An update","volume":"15","author":"Accardi","year":"2018","journal-title":"Immun. Ageing"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s10522-016-9642-z","article-title":"Is immunosenescence influenced by our lifetime \u201cdose\u201d of exercise?","volume":"17","author":"Turner","year":"2016","journal-title":"Biogerontology"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/0167-5699(96)80543-3","article-title":"Thymic involution with ageing: Obsolescence or good housekeeping?","volume":"17","author":"George","year":"1996","journal-title":"Immunol. Today"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.smim.2012.04.008","article-title":"Innate immunosenescence: Effect of aging on cells and receptors of the innate immune system in humans","volume":"24","author":"Solana","year":"2012","journal-title":"Semin. Immunol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.4049\/jimmunol.1401174","article-title":"Aging of the T cell compartment in mice and humans: From no naive expectations to foggy memories","volume":"193","year":"2014","journal-title":"J. Immunol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jgo.2017.08.001","article-title":"Inclusion of elderly or frail patients in randomized controlled trials of targeted therapies for the treatment of metastatic colorectal cancer: A systematic review","volume":"9","author":"Gouverneur","year":"2018","journal-title":"J. Geriatr. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1200\/JCO.2012.41.6727","article-title":"Under-representation of older adults in cancer registration trials: Known problem, little progress","volume":"30","author":"Scher","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1200\/JCO.2018.78.8687","article-title":"Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Chemotherapy: ASCO Guideline for Geriatric Oncology","volume":"36","author":"Mohile","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"973","DOI":"10.2217\/fon-2020-0146","article-title":"Immunotherapy in elderly patients: Should we stay or should we go?","volume":"16","author":"Nunno","year":"2020","journal-title":"Future Oncol."},{"key":"ref_25","unstructured":"American Cancer Society (2023). Cancer Facts & Figures 2023-Special Section: Lung Cancer 2023, American Cancer Society, Inc.. Available online: https:\/\/www.cancer.org\/content\/dam\/cancer-org\/research\/cancer-facts-and-statistics\/annual-cancer-facts-and-figures\/2023\/2023-cff-special-section-lung-cancer.pdf."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"101192","DOI":"10.1016\/j.esmoop.2023.101192","article-title":"Immunotherapy in the first-line treatment of elderly patients with advanced non-small-cell lung cancer: Results of an International Experts Panel Meeting by the Italian Association of Thoracic Oncology (AIOT)","volume":"8","author":"Gridelli","year":"2023","journal-title":"ESMO Open"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ctrv.2017.08.003","article-title":"Immunosenescence and immunecheckpoint inhibitors in non-small cell lung cancer patients: Does age really matter?","volume":"60","author":"Ferrara","year":"2017","journal-title":"Cancer Treat Rev."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.exger.2017.12.025","article-title":"Age effects of distinct immune checkpoint blockade treatments in a mouse melanoma model","volume":"105","author":"Hurez","year":"2018","journal-title":"Exp. Gerontol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"5347","DOI":"10.1158\/1078-0432.CCR-18-1116","article-title":"Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations","volume":"24","author":"Kugel","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1200\/EDBK_201435","article-title":"Immunotherapy in Older Adults with Advanced Cancers: Implications for Clinical Decision-Making and Future Research","volume":"38","author":"Kanesvaran","year":"2018","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1007\/s40266-018-0573-z","article-title":"The Role of Targeted Agents and Immunotherapy in Older Patients with Non-small Cell Lung Cancer","volume":"35","author":"Gomes","year":"2018","journal-title":"Drugs Aging"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1093\/oncolo\/oyac119","article-title":"Immune Checkpoint Inhibitors: The Unexplored Landscape of Geriatric Oncology","volume":"27","author":"Choucair","year":"2022","journal-title":"Oncologist"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.bj.2020.07.009","article-title":"Immunotherapy in older patients with cancer","volume":"44","author":"Granier","year":"2021","journal-title":"Biomed. J."},{"key":"ref_34","unstructured":"IBM Corp (IBM SPSS Statistics for Windows, 2023). IBM SPSS Statistics for Windows, Version 27.0."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.3389\/fonc.2020.01671","article-title":"Impact of Age on the Efficacy of Immune Checkpoint Inhibitor-Based Combination Therapy for Non-small-Cell Lung Cancer: A Systematic Review and Meta-Analysis","volume":"10","author":"Yan","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41590-017-0006-x","article-title":"The twilight of immunity: Emerging concepts in aging of the immune system","volume":"19","year":"2018","journal-title":"Nat. Immunol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.ejca.2019.08.027","article-title":"Older and younger patients treated with immune checkpoint inhibitors have similar outcomes in real-life setting","volume":"121","author":"Corbaux","year":"2019","journal-title":"Eur. J. Cancer"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"558454","DOI":"10.3389\/fonc.2020.558454","article-title":"Clinical Efficacy of Immune Checkpoint Inhibitors in Older Non-small-Cell Lung Cancer Patients: A Meta-Analysis","volume":"10","author":"Sun","year":"2020","journal-title":"Front. Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/1\/145\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:42:55Z","timestamp":1760132575000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/1\/145"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,27]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1]]}},"alternative-id":["cancers16010145"],"URL":"https:\/\/doi.org\/10.3390\/cancers16010145","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,27]]}}}